| dc.contributor.author | Bagire, Pascal Gisenya | |
| dc.contributor.author | Ogwang, Patrick E | |
| dc.contributor.author | Lusi, Jonathan KM | |
| dc.contributor.author | Lusi, Justin Paluku | |
| dc.contributor.author | Daddy, Nsengiyumva Bati | |
| dc.contributor.author | Kahatwa, Serge | |
| dc.contributor.author | Serugendo, Albin | |
| dc.contributor.author | Kihemba, Kasereka | |
| dc.date.accessioned | 2023-10-17T11:41:02Z | |
| dc.date.available | 2023-10-17T11:41:02Z | |
| dc.date.issued | 2022 | |
| dc.identifier.citation | Bagire, P. G., Ogwang, P. E., & Lusi, J. K. M. (2022). Artemisia afra infusions clinical benefits as a complementary treatment to “WHO” approved drugs against tuberculosis. Pharm Pharmacol Int J, 10(5), 157-166. | en_US |
| dc.identifier.uri | http://ir.must.ac.ug/xmlui/handle/123456789/3184 | |
| dc.description.abstract | In the past few years, the number of people infected with pulmonary tuberculosis has increased.1Today, it kills thousands in Africa alone, millions worldwide and the numbers keep on increasing due to COVID-19 (WHO, 2021). Moreover, resistance to conventional anti tuberculosis recommended drugs is increasing thus rendering more and more difficult to treat this deadly disease.2 Currently, one third of the world population is infected with various forms of TB,3 and each year 2-3 million people of the world die from TB infection or its complications.4 Based on an estimate, nearly one billion people were affected by the disease between 2000 and 2020.5 | en_US |
| dc.description.sponsorship | Opalack Foundation and Ilwerliewen | en_US |
| dc.language.iso | en_US | en_US |
| dc.publisher | Pharmacy & Pharmacology International Journal | en_US |
| dc.subject | Pulmonary Tuberculosis | en_US |
| dc.subject | WHO | en_US |
| dc.subject | COVID-19 | en_US |
| dc.subject | Africa | en_US |
| dc.title | Artemisia afra infusions clinical benefits as a complementary treatment to “WHO” approved drugs against tuberculosis | en_US |
| dc.type | Article | en_US |
